Meeting
2023 ASCO Annual Meeting
Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis.
Presenter
Stephanie L. Graff, MD
Lifespan Cancer Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 542)
DOI
10.1200/JCO.2023.41.16_suppl.542
Abstract #
542
Poster Bd #
372
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6).
Speaker: Thomas Meyskens
Videos & Slides
2016 ASCO Annual Meeting
Patient-Reported Outcomes From MA.17R: A Randomized Trial of Extending Adjuvant Letrozole for 5 years After Completing an Initial 5 Years of Aromatase Inhibitor Therapy Alone or Preceded by Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer
Speaker: Julie Lemieux, MD, MSc
Videos & Slides
2016 ASCO Annual Meeting
A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
Speaker: Paul E. Goss, MD, PhD
Videos & Slides
2013 ASCO Annual Meeting
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
Speaker: Richard G. Gray, MA, MSc